Mar 7, 2024 6:00 am EST MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
Feb 22, 2024 7:00 am EST MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
Feb 7, 2024 7:00 am EST MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
Dec 14, 2023 7:30 am EST MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
Oct 26, 2023 7:30 am EDT MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
Oct 24, 2023 7:30 am EDT MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)